Stemcyte Inc.

Stemcyte Inc. company information, Employees & Contact Information

Explore related pages

Related company profiles:

StemCyte is dedicated to expanding the applications of cell therapy to address currently incurable diseases, paving the way for a healthier future through its guiding principle: “Better Cell, Better Life.” Founded in the United States in 1997, StemCyte has established a strong presence in Taiwan and India. To date, it has built a public cord blood bank with over 36,000 units, making it the largest in scale globally, with unparalleled racial diversity and superior quality. StemCyte is also among the few biotechnology companies that operate both public and private cord blood banks. Over the past 20 years, StemCyte has provided more than 2,300 cord blood units to over 350 transplant centers worldwide, supporting the treatment of various diseases. In November 2024, StemCyte became the first private company in the world to obtain FDA approval for a cord blood biologics license. Moving forward, StemCyte will continue its commitment to advancing the development of cord blood cell therapies, ensuring that physicians and patients around the globe have access to safe and effective cell therapy resources. For more information, please visit https://stemcytebio.com/.

Company Details

Employees
171
Founded
-
Address
508 忠孝東路七段, Nangang District,taipei City 115,taiwan, Province Of China
Phone
6264309042
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Nangang District, Taipei City
Looking for a particular Stemcyte Inc. employee's phone or email?

Stemcyte Inc. Questions

News

StemCyte Announces Successful Phase IIa Clinical Trial Results for HPC, Cord Blood in Treating Post-COVID Syndrome: 85% of Patients Experience Complete Relief from Fatigue Symptoms - PR Newswire

StemCyte Announces Successful Phase IIa Clinical Trial Results for HPC, Cord Blood in Treating Post-COVID Syndrome: 85% of Patients Experience Complete Relief from Fatigue Symptoms PR Newswire

Stemcyte First Biotech to Receive FDA Approval of a Cord Blood Derived Cellular Therapeutic - BioInformant

Stemcyte First Biotech to Receive FDA Approval of a Cord Blood Derived Cellular Therapeutic BioInformant

U.S. FDA Approves StemCyte Biologics License Application for REGENECYTE™ Cord Blood Cell Therapy Product - PR Newswire

U.S. FDA Approves StemCyte Biologics License Application for REGENECYTE™ Cord Blood Cell Therapy Product PR Newswire

FDA Approves StemCyte’s Cord Blood Cell Therapy Regenecyte for Unrelated Donor Hematopoietic Progenitor Cell Transplantation Procedures - CGTLive®

FDA Approves StemCyte’s Cord Blood Cell Therapy Regenecyte for Unrelated Donor Hematopoietic Progenitor Cell Transplantation Procedures CGTLive®

StemCyte gains FDA nod for cord blood therapy - The Pharma Letter

StemCyte gains FDA nod for cord blood therapy The Pharma Letter

StemCyte’s HPC Cord Blood Receives RMAT Designation for Long COVID-19 Treatment - BioSpace

StemCyte’s HPC Cord Blood Receives RMAT Designation for Long COVID-19 Treatment BioSpace

Human Umbilical Cord Blood Infusion Improves Fatigue in Long-COVID - Sleep Review

Human Umbilical Cord Blood Infusion Improves Fatigue in Long-COVID Sleep Review

StemCyte Reports Successful Phase I Trial Using Cord Blood to Treat Cerebral Stroke - BioInformant

StemCyte Reports Successful Phase I Trial Using Cord Blood to Treat Cerebral Stroke BioInformant

Cord Blood: Hope for Coming Generations - 台灣光華雜誌 Taiwan Panorama

Cord Blood: Hope for Coming Generations 台灣光華雜誌 Taiwan Panorama

Rutgers Research Partner Stemcyte, Inc., Expands to New Jersey - Rutgers University

Rutgers Research Partner Stemcyte, Inc., Expands to New Jersey Rutgers University

StemCyte Receives Phase II Investigational New Drug (IND) Clearance from the U.S. Food and Drug Administration (FDA) - PR Newswire

StemCyte Receives Phase II Investigational New Drug (IND) Clearance from the U.S. Food and Drug Administration (FDA) PR Newswire

StemCyte Receives Phase II IND Clearance for HLA-Matched Cord Blood Mononuclear Stem Cells (MC001) - BioInformant

StemCyte Receives Phase II IND Clearance for HLA-Matched Cord Blood Mononuclear Stem Cells (MC001) BioInformant

StemCyte Announces Breakthrough Allogeneic Cell Therapy Technology - PR Newswire

StemCyte Announces Breakthrough Allogeneic Cell Therapy Technology PR Newswire

StemCyte to Supply Raw Materials for Immune Cell Therapies Derived from Umbilical Cord Blood - BioInformant

StemCyte to Supply Raw Materials for Immune Cell Therapies Derived from Umbilical Cord Blood BioInformant

Southern California StemCyte Inc. Receives AABB Reaccreditation - PR Newswire

Southern California StemCyte Inc. Receives AABB Reaccreditation PR Newswire

StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy - BioInformant

StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy BioInformant

StemCyte Requests BLA from U.S. FDA for Allogeneic Cord Blood Product - BioInformant

StemCyte Requests BLA from U.S. FDA for Allogeneic Cord Blood Product BioInformant

StemCyte India - 1st Cord Blood Bank in India to Receive International FACT Accreditation - PR Newswire

StemCyte India - 1st Cord Blood Bank in India to Receive International FACT Accreditation PR Newswire

Top Stemcyte Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant